Contact
Please use this form to send email to PR contact of this press release:
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
TO:
Please use this form to send email to PR contact of this press release:
Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis
TO: